mRNA-based cancer vaccines: A new frontier in personalized immunotherapy - PubMed
3 hours ago
- #cancer treatment
- #personalized immunotherapy
- #mRNA vaccines
- mRNA technology advances cancer immunotherapy by enabling personalized tumor-associated or neoantigen vaccines.
- mRNA vaccines are non-integrative, safe, scalable, and faster to produce compared to conventional vaccines.
- Early clinical trials in melanoma, breast, glioblastoma, and pancreatic cancer show promising immunogenicity, especially with checkpoint inhibitors.
- Enteromix, an mRNA cancer vaccine developed in Russia, highlights global potential and clinical accessibility.
- Challenges include tumor heterogeneity, antigen escape, delivery efficiency, and manufacturing logistics.
- Future solutions involve AI, multi-omics integration, and next-generation delivery systems.
- mRNA vaccines represent a revolutionary approach in personalized oncology and next-gen immunotherapy.